Parallel Advisors
KYTX icon

Parallel Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Parallel Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Buy
+1,694
New +$15K ﹤0.01% 2754
2026
Q1 		– Sell
-26
Closed -$244 – 3970
2025
Q4 		$244 Buy
+26
New +$193 ﹤0.01% 3495

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Parallel Advisors's KYTX Position: Q2 2026 in Review

Parallel Advisors opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 1,694 shares worth $15.1K. The stake represents ﹤0.01% of the portfolio and ranks #2754 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in KYTX as recently as Q4 2025.

Parallel Advisors first reported a position in KYTX in Q4 2025 and has held it in 2 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Parallel Advisors held 1,694 shares of Kyverna Therapeutics worth $15.1K as of Q2 2026.
  • Kyverna Therapeutics was a new Parallel Advisors position in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2754 holding.
  • Parallel Advisors first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.